|Targets||Protease-Activated Receptors (PARs)|
|Description||UDM-002555 is a small-molecule and selective antagonist of protease-activated receptor-4 (PAR-4). It can suppress the activation of platelet in dose manner. In combination with aspirin, it inhibited arterial thrombosis with limited impact on hemostasis in cynomolgus monkeys.|
|Brife Description||antagonist of PAR-4, resistant to platelet, arterial thrombosis|
|Synonyms||UDM-002555; UDM 002555; UDM002555|
|Application||the potential treatment of arterial thrombosis|
|Current Developer||Bristol-Myers Squibb|
SLIGKV-NH2 is a protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM; IC50 = 10.4 μM).
FR 171113 is a protease-activated receptor 1 (PAR1) antagonist displaying significant antiplatelet activity in vitro. It inhibits thrombin TRAP-6-induced platel...
E 5555 hydrobromide
E 5555 hydrobromide is a potent and orally bioactive thrombin receptor (or protease-activated receptor 1, PAR1) antagonist (IC50 = 19 nM). It inhibits human pla...
BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vasc...
Atopaxar is a Protease-activated receptor-1 (PAR-1) inhibitor. It can inhibit the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP)...
SCH 79797 dihydrochloride
SCH 79797 dihydrochloride is a potent and selective non-peptide PAR1 receptor antagonist (IC50 = 70 nM). SCH 79797 blocks haTRAP-induced human platelet aggregat...
VKGILS-NH2 is a reversed control peptide for SLIGKV-NH2, which is a protease-activated receptor 2 (PAR2) agonist.
SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently un...